[go: up one dir, main page]

ATE466008T1 - P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält - Google Patents

P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält

Info

Publication number
ATE466008T1
ATE466008T1 AT04774778T AT04774778T ATE466008T1 AT E466008 T1 ATE466008 T1 AT E466008T1 AT 04774778 T AT04774778 T AT 04774778T AT 04774778 T AT04774778 T AT 04774778T AT E466008 T1 ATE466008 T1 AT E466008T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
producing
composition containing
containing same
glycoprotein inhibitor
Prior art date
Application number
AT04774778T
Other languages
English (en)
Inventor
Keuk Chan Bang
Mi Young Cha
Young Gil Ahn
Young Jin Ham
Maeng Sup Kim
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of ATE466008T1 publication Critical patent/ATE466008T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Structural Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AT04774778T 2003-10-07 2004-10-06 P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält ATE466008T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030069582A KR100557093B1 (ko) 2003-10-07 2003-10-07 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PCT/KR2004/002550 WO2005033097A1 (en) 2003-10-07 2004-10-06 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
ATE466008T1 true ATE466008T1 (de) 2010-05-15

Family

ID=36500896

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04774778T ATE466008T1 (de) 2003-10-07 2004-10-06 P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält

Country Status (22)

Country Link
US (1) US7625926B2 (de)
EP (1) EP1678162B1 (de)
JP (1) JP4481992B2 (de)
KR (1) KR100557093B1 (de)
CN (1) CN1863795B (de)
AT (1) ATE466008T1 (de)
AU (1) AU2004277475B2 (de)
BR (1) BRPI0415053B8 (de)
CA (1) CA2541301C (de)
DE (1) DE602004026903D1 (de)
DK (1) DK1678162T3 (de)
ES (1) ES2342290T3 (de)
IL (1) IL174665A (de)
MX (1) MXPA06003803A (de)
NO (1) NO336127B1 (de)
NZ (1) NZ546257A (de)
PL (1) PL1678162T3 (de)
PT (1) PT1678162E (de)
RU (1) RU2317985C1 (de)
SI (1) SI1678162T1 (de)
WO (1) WO2005033097A1 (de)
ZA (1) ZA200603538B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5084269B2 (ja) * 2004-02-18 2012-11-28 アストラゼネカ アクチボラグ テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EA019951B1 (ru) * 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
WO2013175388A1 (en) 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20150135110A (ko) * 2014-05-23 2015-12-02 한미정밀화학주식회사 p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI838700B (zh) 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
WO2020124070A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
US10849893B2 (en) 2018-12-14 2020-12-01 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
US12404267B2 (en) 2019-02-14 2025-09-02 Assia Chemical Industries Ltd. Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
WO2020230037A1 (en) * 2019-05-13 2020-11-19 Dr. Reddy's Laboratories Limited Alternate process for the preparation of encequidar
WO2021044350A1 (en) * 2019-09-04 2021-03-11 Dr. Reddy’S Laboratories Limited Solid forms of encequidar mesylate and processes thereof
WO2022011221A1 (en) 2020-07-10 2022-01-13 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
KR20230104151A (ko) 2020-10-07 2023-07-07 아테넥스, 인크. 아세트아미도-페닐테트라졸 유도체 및 그의 사용 방법
EP4237420A4 (de) * 2020-10-30 2025-03-19 Health Hope Pharma Limited Polymorphismen von hm3018mesylat
CN117603219B (zh) * 2023-11-29 2025-08-08 浙江大学 一种p-糖蛋白抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095213A1 (en) * 1990-11-06 1992-05-07 Jotham W. Coe Quinazoline derivatives for enhancing antitumor activity
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
EP0649410B1 (de) 1992-07-10 1997-05-02 Laboratoires Glaxo Sa Anilide-derivate
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
AU3408901A (en) * 2000-02-15 2001-08-27 Teijin Ltd Cancer remedy comprising anthranilic acid derivative as active ingredient
KR101060971B1 (ko) 2002-05-14 2011-09-01 제노바 리미티드 안트라닐산 유도체 수화물의 제조 방법
KR100580743B1 (ko) 2003-10-08 2006-05-15 한미약품 주식회사 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법

Also Published As

Publication number Publication date
BRPI0415053B8 (pt) 2021-05-25
CA2541301A1 (en) 2005-04-14
RU2317985C1 (ru) 2008-02-27
MXPA06003803A (es) 2006-07-03
WO2005033097A1 (en) 2005-04-14
CN1863795B (zh) 2011-05-18
ES2342290T3 (es) 2010-07-05
US7625926B2 (en) 2009-12-01
JP2007507493A (ja) 2007-03-29
NZ546257A (en) 2009-09-25
NO336127B1 (no) 2015-05-18
IL174665A (en) 2012-10-31
DK1678162T3 (da) 2010-08-02
KR100557093B1 (ko) 2006-03-03
PT1678162E (pt) 2010-05-19
CA2541301C (en) 2010-02-02
JP4481992B2 (ja) 2010-06-16
SI1678162T1 (sl) 2010-07-30
IL174665A0 (en) 2006-08-20
EP1678162B1 (de) 2010-04-28
EP1678162A4 (de) 2008-07-02
EP1678162A1 (de) 2006-07-12
HK1096399A1 (en) 2007-06-01
US20070072900A1 (en) 2007-03-29
AU2004277475A1 (en) 2005-04-14
BRPI0415053A (pt) 2006-11-28
PL1678162T3 (pl) 2010-09-30
CN1863795A (zh) 2006-11-15
AU2004277475B2 (en) 2007-08-09
DE602004026903D1 (de) 2010-06-10
ZA200603538B (en) 2007-09-26
RU2006114427A (ru) 2007-11-20
KR20050033734A (ko) 2005-04-13
NO20062019L (no) 2006-07-06
BRPI0415053B1 (pt) 2019-12-31

Similar Documents

Publication Publication Date Title
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
MXPA05010899A (es) Derivados de 2-aminopirimidina y su uso medico.
DE602004024375D1 (de) Carboxamidderivate
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
DE602004011966D1 (en) Heterocyclylverbindungen
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
AU2003239389A1 (en) Opioid receptor antagonists
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
TW200510370A (en) Urea derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
WO2005016921A3 (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
MXPA05011671A (es) Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos.
EA200401082A1 (ru) Новые соединения бензоиндолина, способ их получения и фармацевтические композиции, которые их содержат
TW200633701A (en) Thioether derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1678162

Country of ref document: EP